SEP 2 2 2003 Under the

PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/602.235 Filing Date TRANSMITTAL June 24, 2003 First Named Inventor **FORM** Olga A. Cabello Art Unit N/A (to be used for all correspondence after initial filing) Examiner Name Not Yet Assigned Attorney Docket Number HO-P02494US1 1 Total Number of Pages in This Submission

ENCLOSURES (Check all that apply) After Allowance Communication Drawing(s) Fee Transmittal Form to Group Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to Group Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request identify below): References **Express Abandonment Request** Request for Refund Return Postcard x Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm FULBRIGHT & JAWORSKI L.L.P. Melissa L. Sistrunk Individual name Signature Date September 22, 2003

Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147061915 US, in an envelope addressed to: Commissioner for Patents A.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 22, 2003

Signature: /

nette (WNUX (Annette Devereux)

hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER 147061915 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the Dated: September 22, 2003 Signature: Unnote Clevereux

Docket No.: HO-P02494US1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Olga A. Cabello, et al.

Application No.: 10/602,235

Art Unit: N/A Filed: June 24, 2003

(Annette Devereux)

INHIBITION OF GENE EXPRESSION IN For:

VERTEBRATES USING DOUBLE-

STANDED RNA (RNAi)

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A copy of each reference on PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 10/602,235 Docket No.: HO-P02494US1

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P02494US1. A duplicate copy of this paper is enclosed.

Dated: September 22, 2003

Respectfully submitted,

Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100 Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorney for Applicant



PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/PT	0		Complete if Known		
	Stitute for form 1440/01 1	J		Application Number	10/602,235	
l 18	NFORMATIO	N DI	SCLOSURE	Filing Date	June 24, 2003	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Olga A. Cabello	
				Art Unit	N/A	
1	(use as many s	sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	HO-P02494US1	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant			
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear		
	AA	US-20020086356-A1	07-04-2002	Tuschl et al.	•		
	AB	US-20020173478-A1	11-21-2002	Gewirtz			
	AC	US-20020162126-A1	10-31-2002	Beach et al.			
	AD	US-20030084471-A1	05-01-2003	Beach et al.			
	AE	US-6,573,099-B2	06-03-2003	Graham			

	FOREIGN PATENT DOCUMENTS								
Examiner Cite		Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T6			
Iriliaais				AC OFNE A LANGE LANGE	Figures Appear	+			
	BA	WO-9949029-A1	09-30-1999	AG-GENE Australia Ltd.					
1	BB	WO-0168836-A2	09-20-2001	Genetica, Inc					
	ВС	WO-0170949-A1	09-27-2001	Benitec Australia Ltd.					
	BD	WO-0175164-A2	10-11-2001	Whitedhead Institute For					
				Biomedical Research et al		1 1			
	BE	WO-0244321-A2	06-06-2002	Maxplanck-Gesellschaft Sur					
				Forderung Der					
				Wissenschaften E.V.					
	BF	WO-03006477-A1	01-23-2003	University of Massechusetts					
	BG	WO-03012052-A2	02-13-2003	The Government of the United					
1				States of America as					
				Represented by the Secretary					
				of the Department of Health					
				and Human Services					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	CA	Wilson et al., "Omportance of Structural Differences between Complementary RNA Molecules to Control of Replication of an IncB Plasmid," Journal of Bacteriology Vol. 179, No. 3, February 1997. pp. 742-753.					
	СВ	Fire et al., "Potent and Specific Genetic Interference by Double-Standard RNA in Caenorhabditis Elegans," Nature Vol. 391, February 19, 1998, pp. 806-811.					
	CC	Franch et al, "Antisense RNA Regulation in Prokaryotes: Rapid RNA/RNA Interaction Facilitated by a General U-turn Loop Structure," J. Mol. Biol. 294, 1999, pp. 1115-1125.					
	CD	Kennerdell et al, "Heritable gene Silencing in Drosophila Using Double-Stranded RNA," Nature Biotechnology Vol. 17, July 2000, pp. 896-898.					
	CE	Caplen et al, "Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate and Vertebrate Systems," PNAS Vol. 98, No. 17, August 14, 2001, pp. 9742-9747.	_				

Examiner	Date	
Signature	 Considered	



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/P	TO		C mplete if Known		
	Stitute for form 1440701			Application Number	10/602,235	
l in	NFORMATIC	DN DI	SCLOSURE	Filing Date	June 24, 2003	
S	TATEMENT	BY	APPLICANT	First Named Inventor	Olga A. Cabello	
1 ~				Art Unit	N/A	
ĺ	(use as many	sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	HO-P02494US1	

CF	Zamore, Phillip, "RNA Interference: Listening to the Sound of Silence," Nature Structural	
CG	Reik et al, "Biotechnologies and Therapeutics: Chromatin as a Target," Current Opinion in	
	Genetics & Development 12, 2002, pp. 233-242.	
СН	Hutvagner et al., "RNAi: Nature Abhors a Double-Strand," Current opinion in Genetics &	
	Development 12, 2002, pp.225-232.	
CI	Hamamda et al., "Effects on RNA Interference in Gene Expression (RNAi) in Cultured	
	Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3'-Ends	
CJ	Hasuwa et al. "Small Interfereing RNA and Gene Silencing in Transgenic Mice and Rats,"	
СК	· · · · · · · · · · · · · · · · · · ·	
	2002.	
CL	Paul et al., "Effective Expression of Small Interferring RNA in Human Cells," Nature	
СМ	Leirdal et al., "Gene Silencing in Mammilian Cells by Performed Samll RNA Duplexes,"	
CN		
co		
СР		
CQ		
CR		
	CG CH CI CJ CK CL CM CN CO	Biology Vol. 8 No. 9, September 2001, pp. 746-750. CG Reik et al, "Biotechnologies and Therapeutics: Chromatin as a Target," Current Opinion in Genetics & Development 12, 2002, pp. 233-242. CH Hutvagner et al., "RNAi: Nature Abhors a Double-Strand," Current opinion in Genetics & Development 12, 2002, pp.225-232. CI Hamamda et al., "Effects on RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3'-Ends of siRNAs," Antisense and Neucleic Acid Drug Development 12, 2002, pp.301-309. CJ Hasuwa et al, "Small Interfereing RNA and Gene Silencing in Transgenic Mice and Rats," FEBS Letters 532, 2002, pp. 227-230. CK RNA Interference, Cosuppression and Related Phenomena Conference, Frebruary 21-26, 2002. CL Paul et al., "Effective Expression of Small Interferring RNA in Human Cells," Nature Biotechnology Vol. 29, May 2002, pp.505-508. CM Leirdal et al., "Gene Silencing in Mammilian Cells by Performed Samll RNA Duplexes," Biochemical and Biophysical Research Communications 295, 2002, pp. 744-748. CN Check, "Patent Flurry Casts Cloud Over Gene Silencing," Nature 417, June 20, 2002, pp. 779. CO Hannon, "RNA Interference," Nature Vol. 418, July 11, 2002, pp.244 - 251. CP Yu et al., "Simultaneous Inhibition of GSK3 a and GSK3B Using Hairpin si RNA Expression Vectors," Molecular Therapy Vol. 7, No. 2, February 7, 2003, pp. 228 - 236. CQ Stewart et al., "Lentivirus-Delivered Stable Gene Silencing by RNAi in Primary Cells," RNA Vol. 9, no. 4, 2003. pp. 493-501.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date Signature Considered			
Signature Considered	Examiner	Date	
	Signature	Considered	

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Application No. (if known): 10/602,235

Attorney Docket No.: HO-P02494US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. ER 147061915 US in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	September 22, 2003	•
	Date	

Signature

Annette Devereux

Typed or printed name of person signing Certificate

Each paper must have its own certificate of mailing, or this certificate must identify

IDS (Citation) by Applicant

each submitted paper.

Note: